Theranostics in India: a Particularly Exquisite Concept or an Experimental Tool

  • Partha S. ChoudhuryEmail author
  • Manoj Gupta


The term theranostics is a combination of a diagnostic tool that helps to define a right therapeutic tool for specific disease and paves the approach towards personalized or precision medicine. In Nuclear Medicine, a diagnostic radionuclide is labeled with the target and once expression is documented, the same target is labeled with a therapeutic radionuclide and treatment is executed. The theranostic concept was applied first time in 1964 in the treatment of thyroid cancer with I-131 (RAI). Over the years, other theranostic radiotracers became available indigenously from the Bhabha Atomic Research Centre (BARC) in the country. Currently Lu-177 is produced in India and peptides like DOTATATE and PSMA are available in a kit form indigenously. At the present time, the radionuclide therapies of oncological disorders which are being performed in India are mainly for neuroendocrine tumors (NET) and metastatic castration resistant prostate cancer (mCRPC). The main constraints pertaining to this concept is the cost of treatment and awareness among the clinicians which are gradually being taken care of by the private health insurance and our participation in disease management group meetings respectively. The theranostic concept has become popular over the years and has the potential for sustained growth.


Theranostics India History Current status Constraints 


Compliance with Ethical Standards

Conflict of Interest

Partha S Choudhury and Manoj Gupta declares that they have no conflict of interest.

Ethical Approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed Consent

The institutional review board of our institute approved this retrospective study, and the requirement to obtain informed consent was waived.


  1. 1.
    Choudhury P, Gupta M. Personalized & precision medicine in cancer: a theranostic approach. Curr Radiopharm. 2017;10:166–70.CrossRefGoogle Scholar
  2. 2.
    Sharma AR. Nuclear medicine in India : a historical journey. Indian J Nucl Med. 2018;33:S5–10.CrossRefGoogle Scholar
  3. 3.
    Das T, Banerjee S. Theranostic applications of Lutetium-177 in radionuclide therapy. Curr Radiopharm. 2016;9:94–01.CrossRefGoogle Scholar
  4. 4.
    Das T, Guleria M, Parab A, Kale C, Shah H, Sarma HD, et al. Clinical translation of (177)Lu-labeled PSMA-617: initial experience in prostate cancer patients. Nucl Med Biol. 2016;43:296–02.Google Scholar
  5. 5.
    Satpati D, Shinto A, Kamaleshwaran KK, Sane S, Banerjee S. Convenient preparation of [(68)Ga]DKFZ-PSMA-11 using a robust single-vial kit and demonstration of its clinical efficacy. Mol Imaging Biol. 2016;18:420–7.CrossRefGoogle Scholar
  6. 6.
    Das T, Banerjee S, Shinto A, Kamaleshwaran KK, Sarma HD. Preparation of therapeutic dose of 177Lu-DOTA-TATE using a novel single vial freeze-dried kit: a comparison with ‘in-situ’ preparation at hospital radiopharmacy. Curr Radiopharm. 2014;7:12–9.CrossRefGoogle Scholar
  7. 7.
    Gupta M, Choudhury PS, Rawal S, Goel HC, Talwar V, Singh A, et al. Initial risk stratification and staging in prostate cancer with prostatic-specific membrane antigen positron emission tomography/computed tomography: a first-stop-shop. World J Nucl Med. 2018;17:261–9.CrossRefGoogle Scholar
  8. 8.
    Gupta M, Choudhury PS, Rawal S, Goel HC, Singh A, Talwar V, et al. Risk stratification and staging in prostate cancer with prostatic specific membrane antigen PET/CTObjective: a one-stop-shop. Hell J Nucl Med. 2017;20:S156.Google Scholar
  9. 9.
    Gupta M, Choudhury PS, Hazarika D, Rawal S. A comparative study of 68Gallium-prostate specific membrane antigen positron emission tomography-computed tomography and magnetic resonance imaging for lymph node staging in high risk prostate cancer patients: an initial experience. World J Nucl Med. 2017;16:186–91.CrossRefGoogle Scholar
  10. 10.
    Gupta M, Choudhury PS, Rawal S, Gupta G. Incremental value of 68-gallium-prostate-specific membrane antigen positron emission tomography/computed tomography in patients with abnormal prostate-specific antigen and benign transrectal ultrasound biopsy. Urol Ann. 2018;10:150–3.CrossRefGoogle Scholar
  11. 11.
    Gupta M, Choudhury PS, Rawal S, Goel HC, Rao SA. Evaluation of RECIST, PERCIST, EORTC, and MDA criteria for assessing treatment response with Ga68-PSMA PET-CT in metastatic prostate cancer patient with biochemical progression: a comparative study. Nucl Med Mol Imaging. 2018;52:420–9.CrossRefGoogle Scholar
  12. 12.
    Gupta M, Choudhury PS, Rawal S, Goel HC, Rao SA. Evaluation of response in patients of metastatic castration resistant prostate cancer undergoing systemic radiotherapy with lutetium177-prostate-specific membrane antigen: a comparison between response evaluation criteria in solid tumors, positron-emission tomography response criteria in solid tumors, European organization for research and treatment of cancer, and MDA criteria assessed by gallium 68-prostate-specific membrane antigen positron-emission tomography-computed tomography. Urol Ann. 2018.
  13. 13.
    Yadav MP, Ballal S, Tripathi M, Damle NA, Sahoo RK, Seth A, et al. Post-therapeutic dosimetry of 177Lu-DKFZ-PSMA-617 in the treatment of patients with metastatic castration-resistant prostate cancer. Nucl Med Commun. 2017;38:91–8.CrossRefGoogle Scholar
  14. 14.
    Yadav MP, Ballal S, Tripathi M, Damle NA, Sahoo RK, Seth A, et al. 177Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy, and quality of life assessment. Eur J Nucl Med Mol Imaging. 2017;44:81–1.Google Scholar
  15. 15.
    Gupta M, Choudhury PS, Rawal S, Goel HC, Talwar V, Dutta KD, et al. Safety profile and therapeutic efficacy of one cycle of Lu-177 PSMA in end stage metastatic castration resistant prostate cancer patients with low performance status. In communication : Urol Ann. 2018.Google Scholar
  16. 16.
    Sen I. Initial experience with targeted alpha therapy in a multispecialty hospital in India. (Personal communication Unpublished).Google Scholar
  17. 17.
    Choudhury PS, Gupta M. Differentiated thyroid cancer theranostics: radioiodine and beyond. Br J Radiol. 2018;91:20180136.CrossRefGoogle Scholar

Copyright information

© Korean Society of Nuclear Medicine 2019

Authors and Affiliations

  1. 1.Department of Nuclear MedicineRajiv Gandhi Cancer Institute and Research Centre DelhiNew DelhiIndia

Personalised recommendations